A pharmaceutical company in Pakistan plans to import the antiviral drug remdesivir, which has shown promise in treating coronavirus patients, from Bangladesh, it said in a stock exchange filing on Friday.
The announcement by Searle Company Limited came a day after 56 virus deaths were recorded by the south Asian nation, its highest toll in a single day.
The firm said it had entered into an exclusive licensing and marketing agreement with Bangladesh's Beximco Pharmaceuticals.
"Searle Pharma is planning to import remdesivir in finished form (ready to use) to meet the country's urgent requirements," the company told the Pakistan Stock Exchange.
Remdesivir, a drug developed by Gilead Sciences, has grabbed attention as one of the most promising treatments for Covid-19, the respiratory disease caused by the virus, which has killed more than 350,000 people globally.
Pakistan's tally of infections stands at 64,000, with 1,317 deaths, but authorities estimate the disease will not peak until June.